Zhang P - Search Results

1

Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.

Zhang X, Zhang P, Qiu H, Fang Y, Liu H, Zhou Y, Xu H, Yu J, Zhang J, Wang M, Shen L, Li J. Zhang X, et al. Among authors: zhang p, zhang j. Adv Ther. 2023 Sep;40(9):3817-3829. doi: 10.1007/s12325-023-02576-0. Epub 2023 Jun 25. Adv Ther. 2023. PMID: 37356078 Free PMC article.

2

Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.

Li J, Zhang J, Zhang Y, Qiu H, Zhou Y, Zhou Y, Zhang X, Zhou Y, Zhu Y, Li Y, Wang M, Shen K, Tao K, Wu X, Wang H, Zhang B, Ling J, Ye Y, Wu X, Qu H, Ma Y, Jiao X, Zheng H, Jin J, Liu Z, Tan M, Fang Y, Zhang P, Zhang N, Lei C, Cai Z, Liang B, Peng Z, Huang Z, Dong J, Shen L. Li J, et al. Among authors: zhang n, zhang b, zhang p, zhang j, zhang x, zhang y. Eur J Cancer. 2024 Jan;196:113439. doi: 10.1016/j.ejca.2023.113439. Epub 2023 Nov 14. Eur J Cancer. 2024. PMID: 37980854 Clinical Trial.

3

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.

Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, Kang M, Yang N, Zhong D, Wang Z, Yu Y, Zhang Y, Zhao J, Qin T, Chen C, Leaw S, Zheng W, Song Y; RATIONALE-312 Study Group. Cheng Y, et al. Among authors: zhang p, zhang y. J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115-1. doi: 10.1016/j.jtho.2024.03.008. Online ahead of print. J Thorac Oncol. 2024. PMID: 38460751 Free article.

4

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study.

Mao L, Fang M, Chen Y, Wei X, Cao J, Lin J, Zhang P, Chen L, Cao X, Chen Y, Guo J, Si L. Mao L, et al. Among authors: zhang p. Clin Cancer Res. 2022 Nov 1;28(21):4642-4648. doi: 10.1158/1078-0432.CCR-22-1528. Clin Cancer Res. 2022. PMID: 36044526 Free PMC article. Clinical Trial.

5

PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: Potential targets to overcome radioresistance in small cell lung cancer.

Deng H, Chen Y, Li P, Hang Q, Zhang P, Jin Y, Chen M. Deng H, et al. Among authors: zhang p. Cancer Pathog Ther. 2022 Sep 27;1(1):56-66. doi: 10.1016/j.cpt.2022.09.001. eCollection 2023 Jan. Cancer Pathog Ther. 2022. PMID: 38328610 Free PMC article. Review.

6

High expression of WTAP is related to poor prognosis in nasopharyngeal carcinoma.

Tao CJ, Zhang P, Chen YY, Chen M. Tao CJ, et al. Among authors: zhang p. Neoplasma. 2023 Apr;70(2):229-239. doi: 10.4149/neo_2023_220828N871. Epub 2023 Mar 24. Neoplasma. 2023. PMID: 36964720

7

Unilateral biportal endoscopic foraminotomy and diskectomy combined with piezosurgery for treating cervical spondylotic radiculopathy with neuropathic radicular pain.

Zhang P, Jin Y, Zhu B, Zheng M, Ying X, Zheng Q. Zhang P, et al. Front Neurol. 2023 Apr 11;14:1100641. doi: 10.3389/fneur.2023.1100641. eCollection 2023. Front Neurol. 2023. PMID: 37114218 Free PMC article.

8

Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy.

Tao CJ, Zhang P, Zhou L, Hu QY, Chen XZ. Tao CJ, et al. Among authors: zhang p. Transl Cancer Res. 2020 Oct;9(10):6392-6401. doi: 10.21037/tcr-20-1773. Transl Cancer Res. 2020. PMID: 35117247 Free PMC article.

9

Efficacy and safety of sustained-release oxycodone compared with immediate-release morphine for pain titration in cancer patients: A multicenter, open-label, randomized controlled trial (SOCIAL).

Pan H, Shen P, Shu Q, Lu L, Qian S, Zhou Y, Han F, Guo Q, Yang Z, Pan J, Xu Q, Zhang P, Wang K. Pan H, et al. Among authors: zhang p. Medicine (Baltimore). 2019 Jun;98(24):e15505. doi: 10.1097/MD.0000000000015505. Medicine (Baltimore). 2019. PMID: 31192908 Free PMC article. Clinical Trial.

10

PI3K/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer.

Deng H, Chen Y, Wang L, Zhang Y, Hang Q, Li P, Zhang P, Ji J, Song H, Chen M, Jin Y. Deng H, et al. Among authors: zhang p, zhang y. Cell Death Dis. 2023 Oct 6;14(10):652. doi: 10.1038/s41419-023-06171-7. Cell Death Dis. 2023. PMID: 37802999 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29,067 results

Search Page